



Representative Legal Matters

Patrick Edwards

- Acting on the divestment of Inceptua to Vesey Street Capital Partners.
- Advising KKR (Health Care Strategic Growth Fund) on the acquisition of the wholesaler and manufacturer, CliniSupplies.
- Advising Sandoz on the divestment of its China business to Aspen Pharma.
- Acting for KKR (Health Care Strategic Growth Fund) on the acquisition of the CRO, Coriolis Pharma.
- Acting for Sandoz on a long-term collaboration agreement with CRO, Just Evotec.
- Acting for Takeda on the divestment of its Austrian manufacturing site to GTCR's portco Corza Medical.
- Advising Baxter on the spin-out of its kidney product division, Vantive.
- Advising Johnson & Johnson on the spin-out of its consumer health division, Kenvue.
- Advising Ingram Micro on the USD 3 billion divestment of its Commerce & Lifecycle Services division to Ceva Logistics (CMA CGM).
- Acting for ICU Medical on its USD 2.7 billion acquisition of Smiths Medical.
- Acting for H.I.G. Capital on the acquisition of Aspire Pharma.
- Advising GSK on the USD 500 million divestments of its global cephalosporin business and related manufacturing and supply arrangements.
- Acting for KKR on its USD 2.5 billion investment in Wella Cosmetics.
- Advising Smith + Nephew on its acquisition of a Portuguese biotech.
- Advising GSK on the divestment of a EUR 1 billion Rabipur and Encepur vaccines business to Bavarian Nordic.
- Acting for Pitney Bowes on the USD 700 million divestments of its O-US logistics software business.
- Advising GSK on the separate divestments of its Canada, Ireland and Italy manufacturing facilities and related manufacturing and supply arrangements.

Baker McKenzie.

- Advising Platinum Equity on the acquisition of the USD 2 billion LifeScan diabetes business from Johnson & Johnson.
- Acting for Astellas on the acquisition of a Cambridge University–based biotech.
- Acting for ICU Medical on the USD 1 billion acquisition of Hospira from Pfizer.